About Ovarian Cancer Treatment Lynparza скачать в хорошем качестве

About Ovarian Cancer Treatment Lynparza

Lynparza (olaparib) is an approved cancer treatment for certain types of advanced ovarian cancers associated with defective BRCA genes. In this new cancer education video, oncologist Dr. Stephen Lemon talks about how Lynparza works, which types of ovarian cancer patients it benefits and what types of sides effects patients may experience from the treatment. As a PARP inhibitor, #Lynparza is the first drug of its kind to be approved in the US. PARP inhibitors are class of medication that offers promise for treating BRCA related cancers. These drugs block an enzyme used by cells to repair damage to their DNA. For women who do not carry the BRCA mutation, PARP inhibitors may work by keeping cancer cells from repairing themselves once they've been damaged by chemotherapy treatment, while sparing healthy cells. These PARP inhibitors may be very effective for patients with BRCA mutations, as their tumor cells will already have problems repairing DNA and the PARP inhibitors will make this even worse. Lynparza is marketed by AstraZeneca Pharmaceuticals. #DrStephenLemon is a medical oncologist in private practice and is not associated with AstraZeneca. #OvarianCancer #StephenLemonMD Dr Stephen Lemon is medical oncologist who now practices at Overlake Cancer Center Bellevue WA. He produces cancer information videos and web related cancer education projects. He invites you to follow his ongoing work at https://www.lightersideofcancer.com/